Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as a unknown/unknown for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in appropriate patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid tumor indications. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable hematologic and cytogenetic responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates and overall survival when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT or PDGFRA mutations.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially around ankles. - Fatigue: general tiredness or lack of energy. - Diarrhea: loose stools, often self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac failure: reduced left ventricular ejection fraction. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure safe use. - Monitor liver function: perform baseline and periodic LFTs. - Assess cardiac status: evaluate ejection fraction before and during therapy. - Check blood counts: regular CBC to detect cytopenias. - Evaluate drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Imatinib levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption, monitor therapeutic response. - Concomitant anticoagulants (e.g., warfarin): may enhance bleeding risk, monitor INR. - Live attenuated vaccines: potential reduced efficacy, assess timing.